Print

Repros Therapeutics Inc. (RPRX) Receives FDA Guidance for Proellex® Low Dose Oral Uterine Fibroid Clinical Program  
11/5/2013 9:49:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has received guidance from the FDA regarding its clinical program for low dose oral Proellex in the treatment of uterine fibroids.

Help employers find you! Check out all the jobs and post your resume.

//-->